|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Nestlé_Health_Science
|
|
gptkbp:acquisitionYear
|
2020
|
|
gptkbp:CEO_(as_of_2020)
|
gptkb:Andrew_Oxtoby
|
|
gptkbp:focusesOn
|
food allergy treatments
|
|
gptkbp:founded
|
2011
|
|
gptkbp:founder
|
gptkb:Stephen_Dilly
|
|
gptkbp:headquarters_location
|
gptkb:Brisbane,_California,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Aimmune Therapeutics
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:listedOn
|
gptkb:NASDAQ
|
|
gptkbp:notableProduct
|
gptkb:Palforzia
|
|
gptkbp:number_of_employees_(2020)
|
approximately 300
|
|
gptkbp:Palforzia_indication
|
peanut allergy
|
|
gptkbp:parentOrganization
|
gptkb:Nestlé_Health_Science
|
|
gptkbp:researchInterest
|
oral immunotherapy
|
|
gptkbp:servesArea
|
gptkb:Europe
gptkb:United_States
|
|
gptkbp:stockSymbol
|
gptkb:AIMT
|
|
gptkbp:type
|
gptkb:subsidiary
|
|
gptkbp:website
|
https://www.aimmune.com/
|
|
gptkbp:bfsParent
|
gptkb:Nestlé_Health_Science
gptkb:Sofinnova_Investments
gptkb:Nestle_Health_Science
|
|
gptkbp:bfsLayer
|
6
|